B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

OKYO Pharma Limited - Ordinary Shares (NQ:OKYO)

1.530 +0.090 (+6.25%)
Streaming Delayed Price Updated: 11:47 AM EDT, Jul 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 117,300
Open 1.450
Bid (Size) 1.510 (200)
Ask (Size) 1.550 (100)
Prev. Close 1.440
Today's Range 1.425 - 1.570
52wk Range 1.340 - 3.349
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Purchase of Shares by Chief Medical Officer
From OKYO Pharma LTD
Via GlobeNewswire

Performance

YTD
-31.4%
-31.4%
1 Month
-2.5%
-2.5%
3 Month
-1.3%
-1.3%
6 Month
-28.8%
-28.8%
1 Year
-45.7%
-45.7%

More News

Read More
News headline image
OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Purchase of Shares by Chairman
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Scientific Advisory Board Meeting and Urcosimod Data Presentation During ASCRS Annual Meeting
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Chairman and Founder Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Director Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Chief Development Officer and Director Acquires Shares
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress
From OKYO Pharma LTD
Via GlobeNewswire
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Friday's session. ↗
Via Chartmill
News headline image
OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares
From OKYO Pharma LTD
Via GlobeNewswire
Which stocks are moving after the closing bell on Thursday? ↗
Via Chartmill
News headline image
OKYO Pharma Announces Public Offering of Ordinary Shares
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
OKYO Pharma Announces Successful Type C Meeting with the FDA
From OKYO Pharma LTD
Via GlobeNewswire
News headline image
FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire

Frequently Asked Questions

Is OKYO Pharma Limited - Ordinary Shares publicly traded?
Yes, OKYO Pharma Limited - Ordinary Shares is publicly traded.
What exchange does OKYO Pharma Limited - Ordinary Shares trade on?
OKYO Pharma Limited - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for OKYO Pharma Limited - Ordinary Shares?
The ticker symbol for OKYO Pharma Limited - Ordinary Shares is OKYO on the Nasdaq Stock Market
What is the current price of OKYO Pharma Limited - Ordinary Shares?
The current price of OKYO Pharma Limited - Ordinary Shares is 1.530
When was OKYO Pharma Limited - Ordinary Shares last traded?
The last trade of OKYO Pharma Limited - Ordinary Shares was at 07/22/26 11:47 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.